A tale of two multi‐focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone‐based OKN‐007

Journal of Cellular and Molecular Medicine

Nataliya Smith¹  Debra Saunders¹  Rheal A. Towner²  Michelle Zalles³  Kar‐Ming Fung⁴  James Battiste⁵  Megan Lerner⁶ 

[1] Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA;Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA;Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA;Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;SurgeryResearch Laboratory, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;

关键词: angiogenesis;    blood perfusion rate (BPR);    ELTD1;    glioblastoma (GBM);    monovalent monoclonal antibody (mmAb);    MRI;    OKN‐007;    orthotopic G55 xenograft model;    tumorigenesis;   

DOI  :  10.1111/jcmm.17133

来源: Wiley

【 授权许可】

CC BY